LA
JOLLA, Calif., Oct. 30,
2024 /PRNewswire/ -- CalciMedica, Inc. ("CalciMedica"
or the "Company") (Nasdaq: CALC), a clinical-stage
biopharmaceutical company focused on developing novel calcium
release-activated calcium ("CRAC") channel inhibition therapies for
acute and chronic inflammatory and immunologic illnesses, today
announced the pricing of an underwritten public offering of
2,720,000 shares of its common stock at a price to the public of
$3.75 per share. The gross proceeds
to the Company from the offering, before deducting underwriting
discounts and commissions and offering expenses, are expected to be
$10,200,000. In addition, the Company
has granted the underwriters a 30-day option to purchase up to an
additional 408,000 shares of its common stock at the public
offering price, less underwriting discounts and commissions. All of
the shares are to be sold by the Company. The offering is expected
to close on or about November 1,
2024, subject to satisfaction of customary closing
conditions.
Jones is acting as the sole book-running manager for the
offering.
The underwritten public offering is being made pursuant to a
shelf registration statement on Form S-3 (File No. 333-273949)
(including a base prospectus) previously filed with the Securities
and Exchange Commission (the "SEC") on August 11, 2023 and declared effective by the SEC
on August 18, 2023. A preliminary
prospectus supplement and the accompanying prospectus relating to
and describing the terms of the underwritten public offering were
filed with the SEC on October 30,
2024. A final prospectus supplement relating to the offering
will be filed with the SEC and will be available on the SEC's
website at www.sec.gov. When available, electronic copies of the
final prospectus supplement and the accompanying prospectus
relating to the underwritten public offering may also be obtained
by contacting: JonesTrading Institutional Services LLC,
Attention: Equity Capital Markets, 325 Hudson Street, 6th Floor
New York, New York 10013; email:
ecm@jonestrading.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or
jurisdiction.
About CalciMedica
CalciMedica is a clinical-stage
biopharmaceutical company focused on developing novel CRAC channel
inhibition therapies for inflammatory and immunologic diseases.
CalciMedica's proprietary technology targets the inhibition of CRAC
channels to modulate the immune response and protect against tissue
cell injury, with the potential to provide therapeutic benefits in
life-threatening inflammatory and immunologic diseases for which
there are currently no approved
therapies. CalciMedica's lead product candidate Auxora™
has demonstrated positive and consistent clinical results in
multiple completed efficacy clinical trials. CalciMedica has
announced data for a Phase 2b trial
(called CARPO – NCT04681066) in patients with AP with SIRS and
completed a Phase 2 trial (called CARDEA – NCT04345614) in
patients with COVID pneumonia. The Company is currently conducting
a Phase 2 trial (called KOURAGE – NCT06374797) in patients
with AKI with associated AHRF with data expected in 2025 and
continuing to support the ongoing Phase 1/2 trial (called CRSPA
– NCT04195347) in patients with AIPT with data expected in
2025. CalciMedica was founded by scientists from Torrey Pines
Therapeutics and the Harvard CBR Institute for Biomedical
Research, and is headquartered in La Jolla, CA.
Forward-Looking Statements
Any statements in this
press release about future expectations, plans and prospects for
CalciMedica, including statements about the timing and completion
of the underwritten public offering, and other statements
containing the words "anticipate," "believe," "estimate," "expect,"
"intend," "may," "plan," "predict," "project," "target,"
"potential," "will," "would," "could," "should," "continue," and
similar expressions, constitute forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors, including: CalciMedica's inability, or the inability of
the underwriter, to satisfy the conditions to closing for the
underwritten public offering; and economic, business,
competitive, and/or regulatory factors affecting the business of
CalciMedica generally. Additional risks and uncertainties that
could cause actual outcomes and results to differ materially from
those contemplated by the forward-looking statements are included
under the caption "Risk Factors" in CalciMedica's Quarterly Report
on Form 10-Q for the quarter ended June 30,
2024 filed with the SEC on August 12,
2024 and other filings CalciMedica makes with the SEC from
time to time and available at www.sec.gov. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. CalciMedica undertakes no obligation
to update such statements to reflect events that occur or
circumstances that exist after the date on which they were made,
except as required by law.
CalciMedica Contact:
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download
multimedia:https://www.prnewswire.com/news-releases/calcimedica-announces-pricing-of-public-offering-of-common-stock-302292275.html
SOURCE CalciMedica, Inc.